Morgan Stanley analyst Jeffrey Hung upgraded Esperion Therapeutics to Equal Weight from Underweight with an unchanged price target of $9. Although the firm still thinks it will take time for Nexletol/Nexlizet sales to ramp up meaningfully, it has greater confidence in the CLEAR outcomes data and believes the shares are likely to appreciate ahead of and through the full data presentation at the American College of Cardiology meeting on March 4.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ESPR:
- RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
- RFK Racing enters team-wide partnership with Esperion
- Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M
- Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
- Esperion call volume above normal and directionally bullish
